Archives
Macrophage-Targeted mRNA Nanoparticles Enhance SCI Recovery
2026-04-30
Macrophage-Targeted Mms6 mRNA Nanoparticles Accelerate Spinal Cord Repair
Study Background and Research Question
Traumatic spinal cord injury (SCI) results in devastating and often permanent neurologic deficits due to limited regenerative capacity in the adult central nervous system. Although acute inflammation is necessary for debris clearance, persistent or dysregulated immune responses can exacerbate tissue damage. Among immune cells, M2-polarized macrophages have emerged as key mediators of CNS repair, both by modulating inflammation and supporting neuronal survival (Fu et al., 2025). However, directly transplanting ex vivo–engineered macrophages faces significant hurdles, including complex cell preparation and the risk of immune rejection. Fu and colleagues addressed whether delivering therapeutic mRNA directly to endogenous macrophages using lipid nanoparticles (LNPs) would offer a more practical and scalable approach for enhancing spinal cord repair.Key Innovation: Targeted mRNA Delivery to Macrophages Using LNPs
The core innovation of this study lies in the design of macrophage-targeted lipid nanoparticles encapsulating mRNA encoding Mms6, a magnetotactic bacterial protein with unique iron-sequestering properties. The rationale is grounded in prior findings that Mms6 can augment macrophage resistance to ferroptosis—an iron-dependent regulated cell death pathway—thereby enhancing their survival and reparative functions after SCI. By functionalizing LNPs with targeting ligands, the authors improved the selective uptake of Mms6 mRNA by lesion-site macrophages in vivo, enabling transient, localized protein expression without genetic modification of the host genome (Fu et al., 2025).Methods and Experimental Design Insights
The investigators synthesized Mms6 mRNA and encapsulated it in LNPs formulated for macrophage targeting. These nanoparticles were administered intravenously to mice immediately following a standardized thoracic spinal cord contusion injury. To rigorously compare delivery strategies, groups received either targeted (Mms6 mRNA-PS/LNPs), non-targeted (Mms6 mRNA-LNPs), or control treatments. Biodistribution and cellular uptake of the mRNA were assessed by fluorescence labeling and quantitative PCR. Functional recovery was measured using established locomotor rating scales over time, while histological analyses quantified scar formation, neuronal survival, and axonal preservation. Selective macrophage depletion experiments confirmed the cell-type specificity and necessity of the therapeutic effect (Fu et al., 2025).Protocol Parameters
- delivery vehicle | lipid nanoparticle (LNP) | in vivo mRNA delivery for gene expression | enables efficient mRNA transfection of macrophages in the injured spinal cord | paper
- injection route | intravenous | murine SCI model | leverages post-injury blood–spinal cord barrier disruption for local delivery | paper
- mRNA payload | Mms6 mRNA | ferroptosis suppression, repair enhancement | encodes bacterial protein conferring iron sequestration and cell survival | paper
- dosage | 1.5 mg/kg (mRNA) | mouse model | optimized for functional rescue and target engagement | paper
- assessment timepoints | days 1–28 post-injury | longitudinal recovery evaluation | captures both acute and chronic repair processes | paper
- reporter gene (workflow) | enhanced green fluorescent protein mRNA | in vivo imaging with fluorescent mRNA | allows visualization and quantification of mRNA delivery efficiency | workflow_recommendation
- capping/chemical modification (workflow) | Cap 1, 5-moUTP | suppression of RNA-mediated innate immune activation | increases translation efficiency and reduces immunogenicity in reporter or therapeutic mRNA assays | workflow_recommendation
Core Findings and Why They Matter
The study demonstrated that targeted Mms6 mRNA-PS/LNPs substantially increased mRNA accumulation within lesion macrophages compared to non-targeted controls, as validated by both fluorescent imaging and molecular quantification. Mice treated with these nanoparticles exhibited superior locomotor recovery, reduced lesion volume, attenuated glial scar formation, and greater preservation of neuronal and axonal structures. Notably, these benefits were abolished when macrophages were depleted, establishing the requirement for endogenous macrophages in mediating the therapeutic effect (Fu et al., 2025). Mechanistically, Mms6 expression in macrophages promoted a reparative, anti-inflammatory phenotype and conferred resistance to ferroptosis, aligning with improved tissue preservation. These findings are significant for several reasons:- They validate the feasibility of non-viral, transient mRNA delivery to CNS-resident immune cells for the purpose of regenerative therapy.
- The approach circumvents the complexities of cell therapy, offering a more clinically tractable platform.
- It demonstrates that modulating iron metabolism and cell death pathways in macrophages can have a profound impact on neuroregeneration.
Comparison with Existing Internal Articles
Several internal resources discuss the use of enhanced green fluorescent protein mRNA and advanced capping/chemical modifications to optimize mRNA delivery, translation, and immune evasion in mammalian systems. For example, EZ Cap™ EGFP mRNA (5-moUTP): Optimized mRNA Delivery & Imaging highlights the importance of Cap 1 analogs and 5-methoxyuridine (5-moUTP) for stabilizing synthetic mRNA and minimizing innate immune activation in both in vitro and in vivo models. Similarly, Capped mRNA for Robust Gene Expression details the advantages of capped mRNA for translation efficiency assays and delivery optimization. While Fu et al. utilized therapeutic Mms6 mRNA, the internal articles focus on reporter mRNAs such as EGFP, but the foundational principles—capping, chemical modification, and poly(A) tail optimization—are directly transferable. The present study's success with LNP-mediated delivery and immune-silent mRNA design is consistent with these internal findings, providing a bridge between reporter assay optimization and translational, disease-model applications.Limitations and Transferability
Despite compelling preclinical results, there are several caveats to consider:- Species Differences: The results are established in a murine SCI model; translation to human patients may be affected by differences in the immune microenvironment, mRNA pharmacokinetics, and scale.
- Delivery Specificity: While targeting ligands increased macrophage uptake, some off-target delivery may occur, necessitating further refinement for clinical applications (Fu et al., 2025).
- Immunogenicity: The study used chemically modified mRNA to minimize immune activation, but long-term safety in humans remains to be fully evaluated.
- Therapeutic Window: Timing of administration post-injury is critical; optimal windows for intervention in human SCI may differ from those in mice.